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Abstract
Purpose: The aims of this study were to prepare a 0.1% Miconazole (MCZ) eye-drop solution and to evaluate the stability and physical properties of 
the preparation.
Methods: For 0.1% MCZ eye-drops (containing 1mg/mL MCZ), a Normal Saline Solution (NSS)-added system in which MCZ injection was diluted with 
NSS, an L-lactate Ringer’s Solution (LRS)-added system diluted with LRS and NSS, and a lactic acid-added system diluted with lactic acid and NSS 
were aseptically prepared. The storage conditions for the NSS-added system were dark condition (25°C, RH84%), cold condition (4°C), and severe 
condition (40°C, RH82%). The LRS-added system and the lactic acid-added system were stored only at 4°C.
Results: MCZ eye-drops diluted with physiological saline showed a reduction in MCZ content to approximately 90% after 2 weeks of storage at 4°C, 
and precipitates were confirmed in the eye-drop solution. The pH was maintained at 4.8 and the osmolality at 280mOsmol/kg. When lactic acid was 
added at concentrations of 1% and 0.5%, MCZ precipitation was confirmed after storage for 4 weeks, and the MCZ content decreased to ≤ 90%, with 
a pH of approximately 3.0-3.5. However, when 0.3% lactic acid was added, the MCZ content was maintained after 4 weeks, but the pH dropped to 
about 3.9.
Conclusion: These results suggest that storing MCZ eye-drops at 4°C for 7 days is reasonable. In addition, the storage period could be extended up 
to 4 weeks under conditions of 25°C, RH84% or 40°C, RH82%. MCZ eye-drop solution containing 0.3% lactic acid can remain stable for 2 weeks when 
stored at 4°C.
Keywords: Miconazole; Eye-drop; Stability; Physical property; Lactic acid; Precipitates
Introduction
The immune system performs a biological defense function in 
humans and protects the body from pathogenic microorganisms 
such as viruses and bacteria. A weakened immune system increases 
the likelihood of fungal corneal infection or fungal intraocular (uvea) 
infection [1-2]. For example, it has been reported that preventing eye 
infections is important in patients receiving chemotherapy and post 
cataract surgery endophthalmitis [3-4]. Fungal keratitisis among the 
most refractory to treatment and can cause corneal blindness [5]. 
In addition, because fungal spores can cause damage to the cornea, 
healing takes time even if antifungal drugs are used. Antifungal drugs 
such as Miconazole (MCZ) and amphotericin B are prescribed in the 
form of eye-drops to prevent eye infections [6-7]. Among them, MCZ 
has a relatively small molecular weight and is more permeable than 
other drugs [8]. However, few antifungal eye drops, including MCZ, 
are not commercially available and are currently being prepared as 
in-hospital formulations as needed [9].
An in-hospital formulation of MCZ eye-drops has been prepared 
using MCZ injection (containing 200mg MCZ per ampoule [20mL]) 
(Figure 1). MCZ is an azole compound having a 5-membered 
imidazole ring containing two nitrogen atoms, and act on the fungi 
membrane system (cell membrane and cell wall) [10]. It is a poorly 
soluble antifungal drug with solubility in water of less than 1 µg/
mL [11]. The injectable preparation contains 60.2g polyoxyethylene 
hydrogenated castor oil and 20mg lactic acid. The MCZ injectable 
preparation is prescribed for infectious diseases such as mycosis, 
pulmonary mycosis, gastrointestinal mycosis, and uromycosis caused 
by Cryptococcus, Candida, Aspergillus, and Coccidioides. The pH 
of the solution is 3.9-4.9, and the osmotic pressure to Normal Saline 
Solution (NSS) is 0.05-0.20.
As a self-imposed control, the MCZ eye-drop solution is stored 
at 4°C (in the dark) for 7 days. When used as an infection control 
agent in patients planned for long-term cancer chemotherapy, 
the stability of MCZ eye-drops for ≥ 7 days needs to be ensured to 
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using high-performance liquid chromatography (HPLC; JASCO 
X-LCTM). Measurement samples containing 900µL acetonitrile, 
100µL MCZ eye-drop solutions, and 10SµL phosphate were divided 
into vials and mixed with a vortex mixer. The wavelength of the 
ultraviolet absorbance detector was set at 224nm. Separation was 
performed with an Inertsil ODS-3 column (4.6 × 150mm, ɸ 5µm) 
at a column temperature of 40°C. The mobile phase consisted of 
acetonitrile/distilled water/phosphoric acid (90:10:1), and the flow 
rate was 0.27mL/min. The measurement was performed two times 
for each sample, and the average value was used for analysis. Based 
on the calibration curve (N=10), the LOD and LOQ of a MCZ were 
determined to be 7.66 and 2.53 µg/mL (y=26498x+3865.3, R2=0.9997).
Measurement of pH: pH was determined using Horiba pH meter 
F-51. pH was measured at N=10 for the NSS-added system and at N=3 
for the lactic acid-added system, and the average values were used for 
analysis.
Measurement of osmotic pressure: Osmotic pressure 
measurements were performed using automatic cryoscopic osmometer 
osmomat® 030-D (Gonotec, Germany). The NSS-added system was 
tested at N=10 and the lactic acid-added system were tested at N=3, 
and the average values were obtained. Osmotic pressure was measured 
two times per sample, and the average value was used for analysis.
Appearance observation: After storage under the different 
conditions, the solutions were visually inspected.
Molecular weight determination using matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry: Molecular 
weight was determined using matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF MS; 
JMS-S3000 Spiral TOF™). Polyethylene glycol 600 was added as a 
standard reference sample to a concentration of 10mg/mL, and a 
standard reference solution was prepared. Α-Cyano-4-hydroxy-silicic 
acid was added to methanol to a concentration of 10mg/mL to prepare 
a matrix solution. To prepare the measurement sample, ethanol 
was added to a concentration of 10mg/mL. The standard reference 
solution/matrix solution was mixed at a 1:10 ratio; the measurement 
sample solution/matrix solution was mixed at 1:10 and spotted; and 
the measurement was performed using the internal standard method. 
The measurement mode was Spiral POS, and the measurement 
method was SP-2000.spmc. The other conditions were mass range 
300-2000m/z, laser intensity 22%, and delay time 180ns.
Statistical processing of data: After performing a one-way ANOVA 
between each group, each group was compared by Tukey’s Test. A risk 
rate of less than 0.05 (p<0.05) was considered statistically significant.
Results
Saline-added system
Quantitation of MCZ using HPLC: Table 1 shows the results of 
MCZ content analysis under storage conditions of 4°C, 40°C, and 
25°C (Figure 2). Immediately after preparation, the MCZ content was 
approximately 1000µg/mL under all conditions. However, the MCZ 
content after storage at 4°C for 2 weeks decreased to about 890µg/mL. 
In addition, after 4 weeks of storage, the MCZ content decreased to 
approximately 710µg/mL. At 40°C and 25°C, the MCZ content after 4 
weeks of storage was maintained at approximately 1000µg/mL.
Measurement of pH: Table 1 shows the pH results of MCZ eye-
drops stored at 4°C, 40°C and 25°C. The pH immediately after 
preparation was about 4.9 under all conditions. The pH of MCZ 
ophthalmic solutions stored at 40°C and 25°C was maintained at 
expect improvements in patient convenience and in the efficiency 
of preparation in the pharmacy department. In other words, if it is 
possible to verify how long the storage period of MCZ eye-drops can 
be extended, it will not only improve the clinical safety for patients 
but also reduce the burden of medication guidance for the medical 
staff [12]. Therefore, the purpose of this study was to prepare 0.1% 
MCZ eye-drops and store the solution at 4°C (in the dark), 40°C and 
82% relative humidity (RH82%) (In the dark), and 25°C and RH84% 
(in the dark). Currently, MCZ eye-drops prepared as in-hospital 
preparations are stored at 4°C, so the LRS-added system and lactic 
acid-added system were stored only at 4°C. We also aimed to evaluate 
the stability and physical properties of the preparation. In addition, 
we report herein the basic challenges to prescribing a new in-hospital 
formulation of MCZ eye-drops.
Materials and Methods
Materials
MCZ injection (MCZ content 200mg/20mL, lot no. A904) was 
purchased from Mochida Pharmaceutical Co., Ltd. Isotonic sodium 
chloride solution (NSS) (lot no. 180903TA) and sodium L-lactate 
Ringer’s Solution (LRS) (lot no. 190418KA) were purchased from 
Terumo Corporation. L-lactic acid (lot no. L0165) was purchased from 
Tokyo Chemical Industry Co., Ltd. All other chemicals used were of 
analytical reagent grade (Fujifilm Wako Pure Chemical Corporation, 
Tokyo, Japan).
Methods
Preparation of MCZ eye-drops: For the NSS-added system, 
MCZ injection was diluted 10 times with NSS to prepare 0.1% MCZ 
eye-drops (containing 1mg/mL MCZ). The prepared eye drops, in 
accordance with the Japanese Pharmacopoeia, 17th Edition (JP XVII), 
1) room temperature and dark conditions (25°C, RH 84%), 2) cold-
temperature condition (4°C), and 3) severe (40°C, RH 82%). Each 
condition was tested at N=10. In the lactic acid addition system, after 
adding so that the lactic acid content was 0.3%, 0.5%, and 1.0%, it was 
diluted with NSS to prepare 0.1% MCZ eye drops. In the LRS addition 
system, after adding LRS to a lactic acid content of 0.3%, 0.5%, and 
1.0%, it was diluted with NSS to prepare 0.1% MCZ eye drops. The 
lactic acid- and LRS-added systems were tested only in the 4°C 
condition, and each eye-drop preparation was tested at N=3. This eye 
drop was prepared on a clean bench by sterile technology based on 
the JP XVII.
Quantitation of MCZ using high-performance liquid 
chromatography: The MCZ content of the solutions was quantitated 
 
Figure 1: Structure of Miconazole.
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approximately pH 4.8-4.9 after 4 weeks of storage. However, at 4°C, 
the pH dropped to about 4.7 after 4 weeks of storage.
Measurement of osmotic pressure: Table 1 shows the osmotic 
pressure results of MCZ eye-drops stored at 4°C, 40°C and 25°C. 
Immediately after preparation, the eye-drop solution with a lactic acid 
content of 1.0% had an osmotic pressure of 254mOsmol/kg, 0.5% had 
an osmotic pressure of 265mOsmol/kg, 0.3% had an osmotic pressure 
of 264mOsmol/kg. The osmotic pressure of the eye-drops immediately 
after preparation was about 266mOsmol/kg at 4°C and 25°C and about 
264mOsmol/kg at 40°C. However, after storage for 4 weeks, it slightly 
increased to about 267mOmol/kg at 4°C, about 276mOmol/kg at 
40°C, and about 272mOmol/kg at 25°C.
Appearance observation: With respect to appearance, the eye-
drop solution was clear immediately after preparation and up to 1 
week after storage in all conditions (Table 1). However, at the 4°C 
condition, white precipitates (floats) were observed on the sides or 
bottom surface of the container after 2 weeks of storage (Figure 3). In 
addition, precipitates were confirmed in almost all containers after 3 
weeks of storage. At the 40°C and 25°C conditions, the solutions were 
clear from immediately after preparation to up to 4 weeks of storage.
Molecular weight measurement using MALDI-TOF MS: In the 
4°C condition, the appearance of white precipitates was confirmed in 
the eye-drop solution. Therefore, to verify that the white precipitates 
were MCZ, molecular weight measurement of the precipitates was 
performed using MALDI-TOF MS (Figure 4). As a result, peaks were 
confirmed at 414.9994, 416.9967, and 418.9935g/mol, indicating that 
the white precipitates were MCZ.
MCZ eye-drops prepared by NSS were found to be stable for 
4 weeks when stored at 25°C. However, the presence of a white 
precipitate was observed at 4°C and confirmed to be MCZ by 
MALDI-TOFMS measurement. MCZ injection consists of MCZ 
(200mg), polyoxyethylene hydrogenated castor oil 60 (2g), and 
lactic acid (20mg/20mL). In other words, since the MCZ injection is 
diluted with NSS, the concentration of lactic acid in the MCZ eye-
drops is decreased. In general, chemical degradation is one of the 
most common changes in the formulation of liquids. This is due to 
changes in pH, ionic strength, and dielectric constant of the solution 
in the direction of destabilizing the drug due to coexistence with other 
ingredients (compounding agents) such as pharmaceutical additives. 
Next, appearance changes include discoloration and precipitation. 
Among these, precipitation is caused by the decrease in solubility of 
the drug substance and the combination drug due to the coexistence 
 
Figure 2: Change in Concentration of MCZ under storage conditions of 
4°C, 40°C, and 25°C at Saline-added system.
Figure 3: Visual observation of MCZ eye-drop container at Saline-added 
system (under storage at 4°C) each sample was under storage at 4°C.
Storage Time (weeks) Temperature 0 week 1 week 2 week 3 week 4 week
MCZ (µg/ml)
4°C 1030.6 ± 25.5 1030.5 ± 20.3 892.4 ± 114.9 788.6 ± 104.9 708.2 ± 94.7
40°C 1013.6 ± 24.1 996.1 ± 20.6 990.7 ± 16.5* 1004.2 ± 43.6* 998.15 ± 32.4*
25°C 1000.6 ± 22.7 990.2 ± 18.1 999.2 ± 13.9* 961.9 ± 16.9* 977.3 ± 17.3*
pH
4°C 4.90 ± 0.01 4.90 ± 0.01 4.85 ± 0.03 4.87 ± 0.04 4.74 ± 0.08
40°C 4.91 ± 0.01 4.82 ± 0.03 4.78 ± 0.02 4.81 ± 0.02 4.82 ± 0.04
25°C 4.89 ± 0.01 4.87 ± 0.02 4.89 ± 0.02 4.92 ± 0.01 4.91 ± 0.01
Osmotic Pressure
(mOmol/kg)
4°C 265.8 ± 1.7 264.2 ± 1.3 264.7 ± 1.9 264.7 ± 1.9 267.2 ± 1.7
40°C 264.2 ± 1.9 267.1 ± 1.9 274.5 ± 8.5 272.4 ± 5.4 276.5 ± 5.6
25°C 266.7 ± 1.9 266.0 ± 1.3 268.5 ± 1.7 271.7 ± 1.3 271.7 ± 0
Appearance
4°C Clear Clear Precipitate Precipitate Precipitate
40°C Clear Clear Clear Clear Clear
25°C Clear Clear Clear Clear Clear
Table 1: Change in MCZ eye-drops stability at 4°C, 40°C, and 25°C.
Values are shown as the mean ± SD. (n=10respectively)*: p<0.05 vs 4°C (tukey’s test).
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of the drug substance and the combination drug. In addition, changes 
in pH caused by the compounding agent are undesirable because they 
may lead to irritation during drug administration, even if they are not 
accompanied by chemical degradation of the drug or discoloration. 
Therefore, it was considered that the decrease in MCZ content in 
ophthalmic solution may be due to the change in pH of the solution 
due to dilution with physiological saline. LRS dilution system and 
lactic acid dilution system was prepared and evaluated for stability, 
assuming that the elution balance would be disrupted due to the 
decrease in lactic acid concentration in MCZ eye drops /NSS.
LRS-added system
Quantitation of MCZ using HPLC: Table 2 show the results of the 
quantitative analysis of MCZ content in eye-drop samples with lactic 
acid contents of 1%, 0.5%, and 0.3% (Figure 5). Immediately after 
preparation, the MCZ content was approximately 1000µg/mL under 
all conditions. MCZ content was maintained at approximately 1000µg/
mL until 1 week of storage under all conditions. However, the MCZ 
content after 2 weeks of storage decreased by about 730µg/mL at 1%, 
about 830µg/mL at 0.5%, and about 840µg/mL at 0.3%. In addition, the 
MCZ content after 4 weeks of storage was reduced to about 500µg/mL 
at 1%, about 540µg/mL at 0.5%, and about 580µg/mL at 0.3%.
Measurement of pH: Table 2 show the results of pH measurement 
of eye-drop samples with lactic acid contents of 1%, 0.5%, and 0.3%. 
Immediately after preparation, the eye-drop solution with a lactic 
acid content of 1.0% had a pH of approximately5.4, 0.5% had a pH of 
approximately 4.9, 0.3% the pH was approximately 5.2. However, after 
storage for 4 weeks, the pH decreased to about 4.9 at 1.0%, about 4.8 at 
0.5%, and about 4.7 at 0.3%.
Measurement of osmotic pressure: Table 2 show the results of the 
osmotic pressure measurements of the eye-drop samples with lactic 
acid contents of 1%, 0.5%, and 0.3%. Immediately after preparation, 
the eye-drop solution with a lactic acid content of 1.0% had an 
osmotic pressure of 254mOsmol/kg, 0.5% had an osmotic pressure 
of 265mOsmol/kg, 0.3% had an osmotic pressure of 264mOsmol/
kg. However, after 4 weeks of storage, the osmotic pressure slightly 
increased to 267mOsmol/kg at 1.0% and 0.5%, decreased to 
approximately 258mOsmol/kg at 0.3%.
Appearance observation: In the appearance observation, the 
solution immediately after preparation and up to 1 week was clear for 
eye-drop samples with lactic acid contents of 1%, 0.5%, and 0.3% (Table 
2). However, white precipitates (floats) were observed on the sides or 
bottom surface of the containers after 4 weeks of storage (Figure 6).
Lactic acid solution-added system
Quantitation of MCZ using HPLC: Table 3 shows the results 
of the quantitative analysis of the eye-drop samples with lactic 
acid contents of 1%, 0.5%, and 0.3% (Figure 7). Immediately after 
preparation, the MCZ content was approximately 1000µg/mL under 
all conditions. MCZ content was maintained at approximately 
1000µg/mL until 3 weeks of storage under all conditions. However, 
the MCZ content after storage for 4 weeks decreased to about 
820µg/mL at 1% and about 760µg/mL at 0.5%. At 0.3% it was 
maintained at about 1000µg/mL.
Measurement of pH: Table 3 show the results of pH measurements 
of the eye-drop samples with lactic acid contents of 1%, 0.5%, and 
0.3%. Immediately after preparation, the eye-drop solution with a 
lactic acid content of 1.0% had a pH of approximately3.4, 0.5% had a 
pH of approximately 3.8, 0.3% the pH was approximately 4.1. However, 
after storage for 4 weeks, the pH decreased to about 3.1 at 1.0%, about 
3.6 at 0.5%, and 3.8 at 0.3%.
Measurement of osmotic pressure: Table 3 show the results of the 
osmotic pressure measurements of the eye-drop samples with lactic 
acid contents of 1%, 0.5%, and 0.3%. Immediately after preparation, 
the eye-drop solution with a lactic acid content of 1.0% had an 
osmotic pressure of 269mOsmol/kg, 0.5% had an osmotic pressure 
of 265mOsmol/kg, 0.3% had an osmotic pressure of 264mOsmol/kg. 
However, after 4 weeks of storage, the osmolality was maintained at 1% 
but decreased to 260mOsmol/kg at 0.5% and to about 260mOsmol/
kg at 0.3%.
Appearance observation: In the appearance observation, the 
eye-drop solution was clear immediately after preparation and up 
to 2 weeks of storage under all conditions (Figure 8a). However, the 
eye-drop samples with lactic acid contents of 1.0% and 0.5% were 
confirmed to have precipitates after 4 weeks of storage. Conversely, 
the eye-drop solution with 0.3% lactic acid was clear until 4 weeks of 
storage (Figure 8b).
 
Figure 4: MALDI-TOF MS for molecular weight measurement of precipitate 
in eye-drop solution.
 
Figure 5: Change in Concentration of MCZ under storage conditions of 4°C, 
at LRS added system (with lactic acid contents of 1%, 0.5%, and 0.3%).
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Storage Time (weeks) Percentage 0 week 1 week 2 week 3 week 4 week
MCZ (µg/ml)
1% 989.5 ± 18.6 969.8 ± 18.1 733 ± 172.9 593 ± 77.9 509.2 ± 27
0.50% 1030.6 ± 25.5 1013.5 ± 20.3 826.1 ± 142.7 708.2 ± 94.7 542.9 ± 44.8
0.30% 973.5 ± 12.3 975.9 ± 7.8 840.4 ± 66.8 672.4 ± 22.2 589.3 ± 17.5
pH
1% 5.49 ± 0.01 5.39 ± 0.03 5.17 ± 0.03 5.04 ± 0.01 4.97 ± 0.03
0.50 4.9 ± 0.01 4.9 ± 0.01 4.9 ± 0.01 4.84 ± 0.05 4.82 ± 0.02
0.30% 5.28 ± 0.01 5.25 ± 0.02 5.05 ± 0.04 4.8 ± 0.01 4.73 ± 0.04
Osmotic Pressure
(mOmol/kg)
1% 253.8 ± 0.5 254.7 ± 1.0 264.7 ± 1.9 267.2 ± 1.7 267 ± 0.4
0.50 265.8 ± 1.7 264.2 ± 1.3 264.7 ± 1.9 267.2 ± 1.7 267.5 ± 1.1
0.30% 264.5 ± 1.0 263.5 ± 0.8 259.5 ± 1.0 258.8 ± 1.0 258 ± 1.8
Appearance
1% Clear Clear Precipitate Precipitate Precipitate
0.50% Clear Clear Precipitate Precipitate Precipitate
0.30% Clear Clear Precipitate Precipitate Precipitate
Values are shown as the mean ± SD, (n=3 respectively).
Table 2: Changes in the stability of MCZ eye-drops at 4°C added with 1%, 0.5% and 0.3% lactate prepared using L-sodium lactate Ringer’s solution.
Storage Time (weeks) Percentage 0 week 1 week 2 week 3 week 4 week
MCZ (µg/ml)
1% 997.7 ± 12.3 1000.8 ± 23.7 971.2 ± 20.4 999.5 ± 6.0 823.1 ± 183.2*
0.50% 981.9 ± 3.7 995.9 ± 16.1 988.4 ± 21.1 1003.6 ± 22.9 769.2 ± 120.7*
0.30% 992.8 ± 16.8 971.8 ± 8.1 974.2 ± 8.9 998 ± 16.4 967 ± 12.8
pH
1% 3.41 ± 0.01 3.32 ± 0.07 3.3 ± 0.03 3.09 ± 0.02 3.11 ± 0.01
0.50 3.85 ± 0.02 3.9 ± 0.06 3.7 ± 0.01 3.5 ± 0.02 3.56 ± 0.02
0.30% 4.17 ± 0.01 4.19 ± 0.03 4.02 ± 0.02 3.86 ± 0.03 3.83 ± 0.03
Osmotic Pressure
(mOmol/kg)
1% 269.8 ± 1.8 269.0 ± 0.5 267.3 ± 2.9 267.6 ± 1.5 270 ± 0.8
0.50 265.3 ± 0.5 264.5 ± 1.5 261.2 ± 1.0 259.8 ± 1.3 260.5 ± 0.8
0.30% 264.2 ± 0.7 263.3 ± 0.7 261 ± 1.3 260.5 ± 2.6 260 ± 1.8
Appearance
1% Clear Clear Clear Clear Precipitate
0.50% Clear Clear Clear Clear Precipitate
0.30% Clear Clear Clear Clear Clear
Table 3: Changes in the stability of MCZ eye-drops at 4°C added with 1%, 0.5% and 0.3% lactic acid prepared.
Values are shown as the mean ± SD (n=3respectively), *: p<0.05 vs 0.3% (tukey’s test).
Figure 6: Visual observation of MCZ eye-drop container (under 
storage at 4°C, 2 weeks).
(a) With 1% lactic acid prepared using L-sodium lactate Ringer’s solution.
(b) With 0.5% lactic acid prepared using L-sodium lactate Ringer’s solution.
(c) With 0.3% lactic acid prepared using L-sodium lactate Ringer’s solution.
 
Figure 7: Change in Concentration of MCZ under storage conditions 
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Discussion
In the eye-drop samples diluted with NSS, the MCZ content 
decreased to approximately 90% after 2 weeks of storage at 4°C. 
Furthermore, white precipitates were confirmed in the solution, 
which were identified to be MCZ. However, at 40°C and 25°C, the 
MCZ content was maintained at almost 100% after 4 weeks. The 
reason why the MCZ content was kept at 25°C and 40°C was thought 
to be related to the temperature-dependent solubility of MCZ. 
Furthermore, significant changes in pH and osmotic pressure were 
observed under all storage conditions. In general, it is known that 
the difference in osmotic pressure does not cause much discomfort in 
ocular tissue at 0.6-2.0% (0.72 as an osmotic pressure ratio) in terms 
of sodium chloride [13]. For example, medical glaucoma eye-drops 
have an osmotic pressure ratio of 0.6 to 1.6 and a pH in the range 
of 4 to 8 [14]. Generally, the pH and osmolality of MCZ eye-drops 
are suitable after 4 weeks. No precipitation was confirmed at 25°C and 
40°C. However, since a precipitate was confirmed at 4°C, the effect 
of temperature was also inferred. Therefore, when stored at 4°C, the 
MCZ content remained reasonable after 1 week of storage. Further, the 
results suggested that room temperature storage (15-25°C) is possible, 
which could improve not only the medication compliance but also the 
convenience of patients. In addition, it could also reduce the burden of 
medication guidance for the medical staff [15].
MCZ eye-drops were prepared by diluting an MCZ injectable 
preparation 10 times with NSS. The MCZ injectable preparation is 
composed of 200mg MCZ, 2g polyoxyethylene-cured castor oil 60, 
and 20mg/20mL lactic acid. Therefore, we hypothesized that diluting 
the MCZ eye-drops 10 times with saline disrupted the dissolution 
balance owing to the decrease in lactic acid concentration. Therefore, 
the stability of the lactic acid and LRS-added systems was evaluated. 
In the LRS-added system, precipitation was confirmed in 2 weeks in 
samples with lactic acid contents of 1%, 0.5%, and 0.3%. In addition, 
the MCZ content decreased. LRS contains Ca and Mg. MCZ nitrate 
creams are commercially available. MCZ is a basic drug containing an 
imidazole ring in its structure, with improved solubility under acidic 
conditions as nitrate (i.e., MCZ is not precipitated), and is considered 
to have good compatibility as a cream formulation [16]. However, in 
the LRS-added system, it was speculated that the lactic acid contained 
in the MCZ injectable preparation and the MCZ interacted and 
became dispersed in the aqueous solution as Ca lactate and Mg lactate, 
which affected the stability of the MCZ eye-drops.
In the lactic acid-added system, precipitates were confirmed at 4 
weeks and the MCZ content was also decreased in the samples with 
0.5% and 1% lactic acid. However, in the case of samples with 0.3% 
lactic acid, precipitation was not observed even after 4 weeks. In 
addition, the MCZ content was maintained at almost 100%. As MCZ 
is a basic drug, it is present in solutions as ions when the pH is acidic. 
However, in eye-drops containing 1% and 0.5% lactic acid with a pH of 
approximately 3.1-3.5, precipitation was confirmed. The pH range of 
the MCZ injection solution (pH 3.9-4.9) was a factor in this result. At 
a lactic acid content of 0.3%, the pH was almost approximately 3.9 after 
4 weeks, which was considered to have contributed to the maintenance 
of the MCZ content. In addition, even if the polyoxyethylene 
hydrogenated castor oil contained in the MCZ injectable preparation 
was diluted with physiological NSS and additional lactic acid was 
added, good compatibility among MCZ, lactic acid, and castor oil was 
obtained, as in the MCZ injectable preparation [10]. However, it was 
inferred that the MCZ content decreased as a result. Not only may the 
effect of pH by adding 0.3% lactic acid to MCZ, but also polyoxyethylene 
hydrogenated castor oil contributes to the stability. Polyoxyethylene 
hydrogenated castor oil is also considered to be an additive necessary 
for the stable dispersion of MCZ in solution. MCZ 0.1% eye-drops are 
currently used as an in-hospital formulation to prevent eye infection 
in patients undergoing cancer chemotherapy. Another fungal drug, 
voriconazole, has also been prepared as an in-hospital formulation in 
the form of eye-drops, and its stability has been reported [17]. In this 
study, MCZ eye drops was found to be stable at 0.3% lactic acid for 4 
weeks from the viewpoint of maintaining the MCZ content. However, 
the pH after storage for 3 weeks was less than 4. Regarding the comfort 
of use for patients, we are concerned about irritation to the eyes. 
From the above, 2 weeks is currently considered to be adequate for 
the stability of the 0.3% lactic acid system. In the present study, the 
decrease in the content of MCZ was suppressed in the lactic acid added 
system. The reason for this may be as follows. In the first place, MCZ 
is a basic drug. In general, many drugs are weakly acidic or weakly 
basic compounds. Drug components coexist in solution as a mixture 
of ionic and nonionic molecules. The pH of the solution in which the 
drug is present is determined by the dissociation constant (pKa) of the 
individual drug, according to the Henderson-Hasselbalch equation 
Figure 8a: Visual observation of MCZ eye-drop container (under 
storage at 4°C, 2 weeks).
(a)With 1% lactic acid prepared using lactic acid reagent.
(b)With 0.5% lactic acid prepared using lactic acid reagent.
(c)With 0.3% lactic acid prepared using lactic acid reagent.
Figure 8b: Visual observation of MCZ eye-drop container (under 
storage at 4°C, 4 weeks).
(a)With 1% lactic acid prepared using lactic acid reagent.
(b)With 0.5% lactic acid prepared using lactic acid reagent.
(c)With 0.3% lactic acid prepared using lactic acid reagent.
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[18]. In other words, in the case of MCZ, the addition of lactic acid 
may contribute to its stability by making it an ionic molecule when the 
liquid nature of the solution is acidic. Moreover, this drug has already 
been clinically applied. In the future, we believe that it is necessary to 
accumulate basic research data on in-hospital formulations to confirm 
their safety and antifungal effects with lactic acid addition through in 
vitro testing.
MCZ injection already contains 60.2g of polyoxyethylene 
hydrogenated castor oil and 20mg of lactic acid. In the future, safety 
tests such as eye irritation will be required in basic research. Also, in 
this study, the stability of MCZ focused on the diluted solution. In the 
future, I would like to work on compatibility with eye-drop containers 
as a research theme.
Conclusion
At 4°C storage, the MCZ content decreased after 2 weeks and 
precipitation of MCZ was confirmed in the eye-drop solution. After 
preparation, eye-drop solutions can be appropriately stored at 4°C for 
1 week. At 25°C storage, the stability of the MCZ eye-drop solution 
was confirmed even after 4 weeks. The stability of the lactic acid-added 
system, in which the eye-drop solution was diluted with lactic acid 
and physiological saline, and that of the LRS-added system were also 
evaluated. Precipitation of MCZ and a decrease in the MCZ content 
were confirmed at 2 weeks in samples with 1%, 0.5%, and 0.3% lactic 
acid from the LRS infusion solution. At 4 weeks, precipitation of MCZ 
and decreased MCZ content were confirmed in the lactic acid-added 
system with 1% and 0.5% lactic acid. No precipitate was detected in 
the sample containing 0.3% lactic acid, and the MCZ content was 
maintained at almost 100% even after 4 weeks. However, a decrease 
in pH was shown to be irritating to the eyes. Therefore, it is suggested 
that the addition of 0.3% lactic acid improves the stability of MCZ eye 
drops and extends the shelf life from 1 week to 2 weeks.
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